Fecal Microbiota Transplantation for Clostridium difficile Infections in Immunocompromised Patients: A Systematic Review

Shogbesan, Oluwaseun; Poudel, Dilli Ram; Jehangir, Asad; Fadahunsi, Opeyemi; Shogbesan, Gbenga; Donato, Anthony J.

doi:10.14309/00000434-201610001-00167

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 The preferred oral antibiotic for C.difficile infection, vancomycin, has a clinical effectiveness that ranges from 40-60% as defined by resolution of diarrhea and systemic symptoms. 30 However, repeated courses of vancomycin for refractory disease that requires a longer antibiotic course or recurrent disease that returns after successful treatment can select for VRE, a common hospital acquired pathogen.…”

Section: Is Fmt a Viable Tool For Asps To Reduce The Threat Of Mmentioning

confidence: 99%

“…A review of existing scientific literature using FMT in immunocompromised patients, including those who have received stem cell transplants, finds it to be effective with a safety profile similar to immunocompetent patients. 59 For example, one study of eighty immunosuppressed patients reported no infections attributable to the FMT. 60 Another review of solid organ transplant recipients found the most common adverse effects were worsening of pre-existing inflammatory bowel disease (25%) and re-activation of existing cytomegalovirus infection (14%).…”

Section: A Clinical Ethicsmentioning

confidence: 99%

See 1 more Smart Citation

The Ethics of Fecal Microbiota Transplant as a Tool for Antimicrobial Stewardship Programs

Murray¹,

Herbst²

2019

J. Law. Med. Ethics

View full text Add to dashboard Cite

Multidrug resistant organisms (MDROs) are a public health threat that have reduced the effectiveness of many available antibiotics. Antimicrobial stewardship programs (ASPs) have been tasked with reducing antibiotic use and therefore the emergence of MDROs. While fecal microbiota transplant (FMT) has been proposed as therapy to reduce patient colonization of MDROs, this will require additional evidence to support an expansion of the current clinical indication for FMT. This article discusses the evidence and ethics of the expanded utilization of FMT by ASPs for reasons other than severe recurrent or refractory Clostridioides (formerly Clostridium) difficile infection.

show abstract

Section: Is Fmt a Viable Tool For Asps To Reduce The Threat Of Mmentioning

confidence: 99%

Section: A Clinical Ethicsmentioning

confidence: 99%